

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

LL/2 (LLC1)

RRID:CVCL_4358

Type: Cell Line

Proper Citation

CLS Cat# 305311, RRID:CVCL_4358

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_4358

Proper Citation: CLS Cat# 305311, RRID:CVCL_4358

Description: Cell line LL/2 (LLC1) is a Cancer cell line with a species of origin Mus musculus (Mouse)

Disease: Malignant tumors of the mouse pulmonary system

Defining Citation: [PMID:7226139](#), [PMID:28599420](#), [PMID:30084848](#), [PMID:31220119](#)

Comments: Caution: Could be identical to 3LL (Cellosaurus=CVCL_5653).

Category: Cancer cell line

Organism: Mus musculus (Mouse)

Name: LL/2 (LLC1)

Synonyms: LL/2 (LLc1), LL/2(LLc1), LL/2, LL2, LLC1, LLC, Lewis lung carcinoma line 1, Lewis lung carcinoma, Lewis Lung Cancer, Lewis-Lung, Lewis Lung

Cross References: BTO:BTO_0000181, BTO:BTO_0000745, CLO:CLO_0007325, CLO:CLO_0050167, CLDB:cl3208, AddexBio:C0016030/5000, ATCC:CRL-1642, BCRC:60050, BCRJ:0145, BioGRID_ORCS_Cell_line:1628, BioSample:SAMN11397632, CCRID:1101MOU-PUMC000673, CCRID:3101MOUTCM7, ChEMBL-Cells:ChEMBL3307859, ChEMBL-Targets:ChEMBL614088, CLS:305311, CLS:400263, ECACC:90020104, GEO:GSE84108, IZSLER:BS TCL 216, KCB:KCB 200781YJ, NCBI_Iran:C587, PRIDE:PXD008733, PubChem_Cell_line:CVCL_4358, RCB:RCB0558, TKG:TKG 0153, TOKU-E:2205, Ubigen:YC-C018, Wikidata:Q54902678

ID: CVCL_4358

Vendor: CLS

Catalog Number: 305311

Record Creation Time: 20250423T101132+0000

Record Last Update: 20260905T185126+0000

Ratings and Alerts

No rating or validation information has been found for LL/2 (LLC1).

No alerts have been found for LL/2 (LLC1).

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 262 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Liu A, et al. (2026) Soluble Uric Acid Drives CD8+ T-cell Exhaustion by Inducing KSR1-Mediated MAPK Hyperactivation. Cancer research, 86(14), 3459.

Liu JP, et al. (2026) Astrocytic Phenotypic Switching in Posterior Piriform Cortex Orchestrates Bone Cancer Pain-Depression Comorbidity via Purinergic-Noradrenergic Signaling. Advanced science (Weinheim, Baden-Wurttemberg, Germany), e23150.

Georgievski A, et al. (2026) Valrubicin-loaded immunoliposomes targeting antigens on immunosuppressive cells to circumvent resistance to cancer immunotherapy. Cell reports. Medicine, 7(3), 102632.

Li L, et al. (2026) EBF3 suppresses lung adenocarcinoma progression and immune evasion via transcriptional repression of CCL24. Cellular oncology (Dordrecht, Netherlands), 49(3).

Marco S, et al. (2026) Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity. Cancer cell, 44(5), 995.

Wang J, et al. (2026) The phosphatase DUSP2 constrains lymphoid remodeling and immunotherapy response in lung squamous carcinoma. Molecular therapy : the journal of the American Society of Gene Therapy, 34(7), 4279.

Liu Y, et al. (2026) Mitofusin-2 suppresses tumor immune escape through EGFR/STAT3-mediated PD-L1 transcription. Cell death & disease, 17(1).

Jiang YY, et al. (2026) Ze-qi Decoction Inhibits Neutrophil Extracellular Trap Formation to Suppress the Progression and Metastasis of Non-Small Cell Lung Cancer. Integrative

cancer therapies, 25, 15347354261420750.

Cheng Y, et al. (2026) JAK inhibitors alleviate EGFR-inhibitor-induced diarrhea by protecting intestinal stem cells from adaptive-immune-exacerbated injury. *Nature communications*, 17(1).

Aouad S, et al. (2026) Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy. *Journal for immunotherapy of cancer*, 14(4).

Cai J, et al. (2026) LM-101, an Anti-SIRP α Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 32(12), 2391.

Van Le T, et al. (2026) Cooperative IFN- γ and TLR9 signaling reprogram tumor-associated macrophages to enhance antitumor immunity in melanoma. *Biochemical and biophysical research communications*, 831, 154245.

Cao Z, et al. (2026) Study on the mechanism of PSENEN in modulating cisplatin resistance in NSCLC through stromal cell interactions. *International immunopharmacology*, 169, 116037.

Gao H, et al. (2026) Real-Time In Vivo Cellular-Level Imaging During Puncture. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, e15110.

Xu HW, et al. (2026) GM-CSF Armed Oncolytic Adenovirus Enhances T-Cell Infiltration and Suppresses Local and Distal Tumor Growth. *Viruses*, 18(1).

Wei T, et al. (2026) Metabolic-epigenetic regulation of TRPM3 via H3K18 lactylation in dorsal root ganglia mediates bone cancer pain and its attenuation by microwave ablation. *Cancer letters*, 649, 218505.

Yu Q, et al. (2026) Gut microbiota-associated nutritional-immune status predicts prognosis in postoperative NSCLC patients. *Gut microbes*, 18(1), 2652460.

Xu D, et al. (2026) Nanoreactor-enabled PANoptosis via ZBP1 activation potentiates immunotherapy in non-small cell lung cancer. *Biomaterials*, 328, 123894.

Gao L, et al. (2026) The S100A8/A9 complex promotes food intake and prevents adipose tissue loss during cancer cachexia in mice. *Cell metabolism*, 38(5), 909.

Al-Azzam S, et al. (2026) Multi-omics profiling reveals microenvironmental remodeling as a key driver of house dust mite-induced lung cancer progression. *Neoplasia (New York, N.Y.)*, 73, 101275.